News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
698,794 Results
Type
Article (39687)
Company Profile (247)
Press Release (658860)
Multimedia
Podcasts (49)
Webinars (12)
Section
Business (204163)
Career Advice (2007)
Deals (35418)
Drug Delivery (95)
Drug Development (81044)
Employer Resources (172)
FDA (16180)
Job Trends (14858)
News (345183)
Policy (32538)
Tag
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (85)
Alliances (49431)
ALS (88)
Alzheimer's disease (1378)
Antibody-drug conjugate (ADC) (124)
Approvals (16185)
Artificial intelligence (253)
Autoimmune disease (21)
Automation (16)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (175)
Bladder cancer (78)
Brain cancer (27)
Breast cancer (278)
Cancer (2256)
Cardiovascular disease (174)
Career advice (1676)
Career pathing (30)
CAR-T (151)
Cell therapy (422)
Cervical cancer (19)
Clinical research (65985)
Collaboration (832)
Compensation (529)
Complete response letters (19)
COVID-19 (2588)
CRISPR (40)
C-suite (241)
Cystic fibrosis (100)
Data (2204)
Decentralized trials (2)
Denatured (18)
Depression (43)
Diabetes (270)
Diagnostics (6369)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (98)
Drug shortages (25)
Duchenne muscular dystrophy (93)
Earnings (86624)
Editorial (36)
Employer branding (21)
Employer resources (146)
Events (112390)
Executive appointments (722)
FDA (17439)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (747)
Gene editing (104)
Generative AI (19)
Gene therapy (301)
GLP-1 (707)
Government (4415)
Grass and pollen (4)
Guidances (65)
Healthcare (18814)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (115)
Indications (29)
Infectious disease (2730)
Inflammatory bowel disease (137)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (96)
Interviews (311)
IPO (16507)
IRA (40)
Job creations (3631)
Job search strategy (1422)
Kidney cancer (10)
Labor market (38)
Layoffs (467)
Leadership (17)
Legal (7911)
Liver cancer (75)
Lung cancer (320)
Lymphoma (154)
Machine learning (7)
Management (58)
Manufacturing (303)
MASH (67)
Medical device (13378)
Medtech (13383)
Mergers & acquisitions (19455)
Metabolic disorders (683)
Multiple sclerosis (80)
NASH (16)
Neurodegenerative disease (88)
Neuropsychiatric disorders (27)
Neuroscience (1913)
NextGen: Class of 2025 (6512)
Non-profit (4480)
Now hiring (39)
Obesity (362)
Opinion (204)
Ovarian cancer (75)
Pain (87)
Pancreatic cancer (83)
Parkinson's disease (148)
Partnered (21)
Patents (233)
Patient recruitment (112)
Peanut (46)
People (57300)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20557)
Phase II (29056)
Phase III (21648)
Pipeline (1200)
Policy (138)
Postmarket research (2563)
Preclinical (8738)
Press Release (64)
Prostate cancer (106)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (378)
Real estate (5907)
Recruiting (65)
Regulatory (22280)
Reports (46)
Research institute (2320)
Resumes & cover letters (349)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (69)
Series A (130)
Series B (84)
Service/supplier (11)
Sickle cell disease (52)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3576)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (39)
The Weekly (29)
Vaccines (688)
Venture capitalists (41)
Weight loss (234)
Women's health (35)
Worklife (16)
Date
Today (203)
Last 7 days (894)
Last 30 days (2641)
Last 365 days (32893)
2025 (10684)
2024 (35218)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32110)
2016 (31481)
2015 (37555)
2014 (31321)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (718)
Alabama (53)
Alaska (7)
Arizona (232)
Arkansas (13)
Asia (37838)
Australia (6184)
California (6122)
Canada (2012)
China (523)
Colorado (266)
Connecticut (274)
Delaware (147)
Europe (81239)
Florida (911)
Georgia (206)
Idaho (57)
Illinois (535)
India (25)
Indiana (307)
Iowa (11)
Japan (162)
Kansas (104)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (893)
Massachusetts (4564)
Michigan (220)
Minnesota (390)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1725)
New Mexico (28)
New York (1744)
North Carolina (965)
North Dakota (8)
Northern California (2679)
Ohio (204)
Oklahoma (14)
Oregon (34)
Pennsylvania (1375)
Puerto Rico (12)
Rhode Island (33)
South America (1096)
South Carolina (23)
South Dakota (1)
Southern California (2298)
Tennessee (101)
Texas (906)
United States (23092)
Utah (180)
Virginia (145)
Washington D.C. (61)
Washington State (550)
West Virginia (3)
Wisconsin (54)
698,794 Results for "nuvasive inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Globus Medical Completes Merger with NuVasive
Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced it has completed its previously announced merger with NuVasive, Inc.
September 1, 2023
·
7 min read
Business
NuVasive Announces Conference Call and Webcast of Second Quarter 2023 Results
NuVasive, Inc. announced today that it will release its second quarter 2023 results on Wednesday, August 2, 2023 , after the close of the market.
July 24, 2023
·
2 min read
Business
NuVasive Announces Second Quarter 2023 Financial Results
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2023.
August 2, 2023
·
25 min read
Press Releases
Life Spine, Inc. Appoints Richard Mueller as President & Chief Executive Officer
April 1, 2025
·
1 min read
Biotech Beach
NuVasive to Participate in Upcoming March 2023 Investor Conferences
NuVasive, Inc. announced that NuVasive management will participate in upcoming investor conferences and will be joined by Globus Medical management to discuss the two companies’ recent merger announcement and other business topics.
February 27, 2023
·
6 min read
Business
NuVasive Announces Conference Call and Webcast of First Quarter 2023 Results
NuVasive, Inc. announced today the Company will release its first quarter 2023 results on Wednesday, May 10, 2023, after the close of the market.
May 4, 2023
·
2 min read
Pharm Country
Five-Year Study Outcomes of the NuVasive Simplify Cervical Disc were Presented at the North American Spine Society 38th Annual Meeting
Globus Medical, Inc., a leading musculoskeletal solutions company, presented five-year outcomes from the NuVasive Simplify Cervical Disc study at the North American Spine Society 38th Annual Meeting.
October 24, 2023
·
5 min read
Biotech Beach
NuVasive to Participate in Upcoming Global Spine Conferences
NuVasive, Inc., the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced its continued participation at various global conferences throughout April and May.
April 11, 2023
·
3 min read
Deals
NuVasive Shareholders Approve Merger Agreement with Globus Medical
NuVasive, Inc. (NASDAQ: NUVA) today announced that at the special meeting of shareholders held earlier today, its shareholders voted to approve the adoption of the Company’s merger agreement with Globus Medical (NYSE: GMED).
April 27, 2023
·
9 min read
Business
NuVasive Announces First Quarter 2023 Financial Results
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2023.
May 10, 2023
·
22 min read
1 of 69,880
Next
